These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9337685)

  • 1. Pharmacokinetics of amifostine and its metabolites in patients.
    Korst AE; Eeltink CM; Vermorken JB; van der Vijgh WJ
    Eur J Cancer; 1997 Aug; 33(9):1425-9. PubMed ID: 9337685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
    Korst AE; Gall HE; Vermorken JB; van der Vijgh WJ
    Cancer Chemother Pharmacol; 1996; 39(1-2):162-6. PubMed ID: 8995515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
    van der Vijgh WJ; Korst AE
    Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.
    Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR
    Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
    Souid AK; Fahey RC; Dubowy RL; Newton GL; Bernstein ML
    Cancer Chemother Pharmacol; 1999; 44(6):498-504. PubMed ID: 10550571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-performance liquid chromatographic assay using electrochemical detection for the combined measurement of amifostine, WR 1065 and the disulfides in plasma.
    Korst AE; Vermorken JB; van der Vijgh WJ
    J Chromatogr B Biomed Sci Appl; 1997 May; 693(1):167-74. PubMed ID: 9200531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
    Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
    Fouladi M; Stempak D; Gammon J; Klein J; Grant R; Greenberg ML; Koren G; Baruchel S
    Cancer; 2001 Aug; 92(4):914-23. PubMed ID: 11550166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure.
    Cassatt DR; Fazenbaker CA; Bachy CM; Kifle G; McCarthy MP
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):901-7. PubMed ID: 15708273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.
    Korst AE; van der Sterre ML; Gall HE; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
    Clin Cancer Res; 1998 Feb; 4(2):331-6. PubMed ID: 9516919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
    Souid AK; Dubowy RL; Blaney SM; Hershon L; Sullivan J; McLeod WD; Bernstein ML
    Clin Cancer Res; 2003 Feb; 9(2):703-10. PubMed ID: 12576438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
    Levi M; DeRemer SJ; Dou C; Ensminger WD; Smith DE
    Biopharm Drug Dispos; 2004 Jan; 25(1):27-35. PubMed ID: 14716750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic profile of amifostine.
    Shaw LM; Bonner H; Lieberman R
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):18-22. PubMed ID: 8783662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
    Korst AE; van der Sterre ML; Eeltink CM; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
    Clin Cancer Res; 1997 May; 3(5):697-703. PubMed ID: 9815738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy.
    Feng M; Smith DE; Normolle DP; Knol JA; Pan CC; Ben-Josef E; Lu Z; Feng MR; Chen J; Ensminger W; Lawrence TS
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1441-7. PubMed ID: 22440042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood thiols following amifostine and mesna infusions, a pediatric oncology group study.
    Souid AK; Fahey RC; Aktas MK; Sayin OA; Karjoo S; Newton GL; Sadowitz PD; Dubowy RL; Bernstein ML
    Drug Metab Dispos; 2001 Nov; 29(11):1460-6. PubMed ID: 11602522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
    Betticher DC; Anderson H; Ranson M; Meely K; Oster W; Thatcher N
    Br J Cancer; 1995 Dec; 72(6):1551-5. PubMed ID: 8519676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
    Fulda S; Fichtner I; Hero B; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):199-202. PubMed ID: 11464883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the cytoprotective agent WR-2721 (Amifostine, Ethyol) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography.
    Souid AK; Newton GL; Dubowy RL; Fahey RC; Bernstein ML
    Cancer Chemother Pharmacol; 1998; 42(5):400-6. PubMed ID: 9771955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration.
    Ranganathan K; Simon E; Lynn J; Snider A; Zhang Y; Nelson N; Donneys A; Rodriguez J; Buchman L; Reyna D; Lipka E; Buchman SR
    Pharm Res; 2018 Mar; 35(5):99. PubMed ID: 29556791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.